As Covid-related challenges weigh on patient recruitment, biotech scraps PhIIb/III Parkinson's program

Amber Tong

More than two years after little Swiss biotech Addex Therapeutics postponed a Phase IIb/III trial indefinitely due to the then-nascent Covid-19 pandemic, it’s throwing in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

As Covid-related challenges weigh on patient recruitment, biotech scraps PhIIb/III Parkinson's program

Amber Tong

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Pfizer CEO says opportunities with Trump ‘clearly outweigh’ the risks for pharma

Trump blog: Judge extends nationwide block on NIH payment cuts

RFK Jr. readies review of childhood vaccine schedule after pledging not to

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

As Covid-re­lat­ed chal­lenges weigh on pa­tient re­cruit­ment, biotech scraps PhI­Ib/III Parkin­son's pro­gram

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

As Covid-related challenges weigh on patient recruitment, biotech scraps PhIIb/III Parkinson's program